Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR 1,038.60
+2.15 (0.21%)
May 22, 2026, 3:30 PM IST
Zydus Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 267,197 | 232,415 | 195,474 | 172,374 | 151,099 |
Other Revenue | 4,287 | - | - | - | - |
| 271,484 | 232,415 | 195,474 | 172,374 | 151,099 | |
Revenue Growth (YoY) | 16.81% | 18.90% | 13.40% | 14.08% | 4.90% |
Cost of Revenue | 72,926 | 65,384 | 63,937 | 64,707 | 56,857 |
Gross Profit | 198,558 | 167,031 | 131,537 | 107,667 | 94,242 |
Selling, General & Admin | 44,179 | 51,539 | 42,454 | 37,648 | 32,472 |
Other Operating Expenses | 82,433 | 46,726 | 36,047 | 34,263 | 29,873 |
Operating Expenses | 140,692 | 107,429 | 86,145 | 79,139 | 69,501 |
Operating Income | 57,866 | 59,602 | 45,392 | 28,528 | 24,741 |
Interest Expense | -4,389 | -935 | -440 | -1,255 | -1,144 |
Interest & Investment Income | - | 1,862 | 1,281 | 768 | 696 |
Earnings From Equity Investments | 971 | 578 | 1,184 | 946 | 462 |
Currency Exchange Gain (Loss) | 12,805 | 1,634 | 806 | 2,843 | 1,482 |
Other Non Operating Income (Expenses) | 5,095 | 31 | -11 | 251 | 622 |
EBT Excluding Unusual Items | 72,348 | 62,772 | 48,212 | 32,081 | 26,859 |
Merger & Restructuring Charges | -245 | - | -177 | -101 | - |
Impairment of Goodwill | - | -1,350 | - | -5,941 | - |
Gain (Loss) on Sale of Investments | - | 590 | 1,385 | 596 | 874 |
Gain (Loss) on Sale of Assets | - | 345 | 134 | 208 | -17 |
Asset Writedown | - | -846 | - | - | - |
Other Unusual Items | -4,921 | -666 | -281 | - | 1,127 |
Pretax Income | 67,182 | 60,845 | 49,273 | 26,843 | 28,843 |
Income Tax Expense | 15,947 | 14,119 | 9,775 | 5,878 | 5,117 |
Earnings From Continuing Operations | 51,235 | 46,726 | 39,498 | 20,965 | 23,726 |
Earnings From Discontinued Operations | - | - | 230 | -46 | 22,457 |
Net Income to Company | 51,235 | 46,726 | 39,728 | 20,919 | 46,183 |
Minority Interest in Earnings | -835 | -1,471 | -1,133 | -1,316 | -1,310 |
Net Income | 50,400 | 45,255 | 38,595 | 19,603 | 44,873 |
Net Income to Common | 50,400 | 45,255 | 38,595 | 19,603 | 44,873 |
Net Income Growth | 11.37% | 17.26% | 96.88% | -56.31% | 110.32% |
Shares Outstanding (Basic) | 1,006 | 1,006 | 1,012 | 1,016 | 1,024 |
Shares Outstanding (Diluted) | 1,006 | 1,006 | 1,012 | 1,016 | 1,024 |
Shares Change (YoY) | -0.00% | -0.56% | -0.37% | -0.79% | - |
EPS (Basic) | 50.09 | 44.97 | 38.14 | 19.30 | 43.83 |
EPS (Diluted) | 50.09 | 44.97 | 38.14 | 19.30 | 43.83 |
EPS Growth | 11.37% | 17.92% | 97.61% | -55.97% | 110.32% |
Free Cash Flow | -12,774 | 50,641 | 22,897 | 16,579 | 9,019 |
Free Cash Flow Per Share | -12.70 | 50.33 | 22.63 | 16.32 | 8.81 |
Dividend Per Share | 1.000 | 11.000 | 3.000 | 6.000 | 2.500 |
Dividend Growth | -90.91% | 266.67% | -50.00% | 140.00% | -28.57% |
Gross Margin | 73.14% | 71.87% | 67.29% | 62.46% | 62.37% |
Operating Margin | 21.32% | 25.64% | 23.22% | 16.55% | 16.37% |
Profit Margin | 18.57% | 19.47% | 19.74% | 11.37% | 29.70% |
Free Cash Flow Margin | -4.71% | 21.79% | 11.71% | 9.62% | 5.97% |
EBITDA | 72,576 | 68,303 | 52,572 | 35,344 | 31,695 |
EBITDA Margin | 26.73% | 29.39% | 26.90% | 20.50% | 20.98% |
D&A For EBITDA | 14,710 | 8,701 | 7,180 | 6,816 | 6,954 |
EBIT | 57,866 | 59,602 | 45,392 | 28,528 | 24,741 |
EBIT Margin | 21.32% | 25.64% | 23.22% | 16.55% | 16.37% |
Effective Tax Rate | 23.74% | 23.21% | 19.84% | 21.90% | 17.74% |
Revenue as Reported | 276,579 | 235,110 | 198,315 | 174,240 | 153,346 |
Advertising Expenses | - | 3,368 | 2,957 | 2,573 | 2,514 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.